For health, sport and active life
Pharmaceutical products
Anti-counterfeiting System
DYNALAN®-R3 Long

DYNALAN®-R3 Long

COMPOSITION:

One vial contains Powder for injection of LR3IGF-1(r DNA origin) 100 mcg and other ingredients: 40mg Mannitol, 3mg sodium phosphate(0.36 monobasis-sodium phosphate and 2.64 mg biradical-sodium phosphate).


INTRODUCTION:

LR3IGF-1 is produced by gene recombination DNA technology. It has 13 additional amino acids to the N-terminus of IGF-1 , which force the over expressed recombinant peptide into inclusion bodies and stabilize the peptide. In addition, the amino acid in the LR3IGF-1 corresponding to the third amino acid of human IGF-1 nature peptide is mutated from Glu to Arg, which alters the combination between LR3IGF-1 and IGFBP and advances the combination to IGF-1 receptor. Its molecular weight is 9110 daltons. LR3IGF-1 is an asepsis and freeze-dried powder. It can be used in subcutaneous injection diluted with water. After dilution, this substance is close to liquid state.

INDICATIONS:

Stimulates muscle growth, Helps burn fat, Encourages the absorption of Chondroitin Sulfate and Glucosamine Sulfate, Regenerates nerve tissue, Improves the production of white blood cells, Decreases LDL Cholesterol.

DOSAGE AND ADMINISTRATION:

Preprandial glucose monitoring should be considered at treatment initiation and until a well tolerated dose is established. If frequent symptoms of hypoglycemia or severe hypoglycemia occur, preprandial glucose monitoring should continue. The dosage of LR3IGF-1 should be individualized for each patient. The recommended starting dose of LR3IGF-1 is 50mcg per day by subcutaneous injection. If well-tolerated for at least one week, the dose may be increased by 100mcg per day, to the maximum dose 200mcg given twice daily. IGFD and, due to potential hypoglycemic effects, should not be used. If hypoglycemia occurs with recommended doses, despite adequate food intake, the dose should be reduced. LR3IGF-1 should be administered shortly before or after (± 20 minutes) a meal or snack. If the patient is unable to eat shortly before or after a dose for any reason, that dose of LR3IGF-1 should be withheld. Subsequent doses of LR3IGF-1 should never be increased to make up for one or more omitted dose. LR3IGF-1 injection sites should be rotated to a different site with each injection. LR3IGF-1 should be administered using sterile disposable syringes and needles. The syringes should be of small enough volume that the prescribed dose can be withdrawn from the vial with reasonable accuracy.

PHARMACEUTICAL FORM:

25 vials with lyophilizate in cardboard pack with application data sheet.

STORAGE:

Before Opening – Store new unopened vials of LR3IGF-1 in the refrigerator (not the freezer) between 35º to 46ºF (2º to 8ºC). Do not freeze LR3IGF-1. Keep LR3IGF-1 out of direct heat and bright light. If a vial freezes, throw it away. After Opening: once a vial of LR3IGF-1 is opened, you can keep it in the refrigerator between 35º to 46ºF (2º to 8ºC) for 30 days after you start using the vial.

PRODUCTS FROM
POSTTRAUMATIC REHABILITATION

Clinical Products

DYNALAN®-R3 Long
CREATON®
TURABOLONE®
ECDYSTERON®

Research peptides

MGF
PEG MGF
TB-500



About us
Logos
Contacts